Clinical Trials Logo

Acute Myeloid Leukemia, Adult clinical trials

View clinical trials related to Acute Myeloid Leukemia, Adult.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03902665 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia, Adult

Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75

Start date: March 15, 2019
Phase: Phase 2
Study type: Interventional

Patients with acute myeloid leukemia aged 65-75 have a very poor prognosis, irrespective of the treatment strategy, including demethylating agents or conventional chemotherapy. With these approaches, remission rates do not exceed 40%, and overall disease-free survival at 1 year is in the order of 15%. The hypothesis is that up-front allogeneic hematopoietic stem cell transplant will produce a complete remission rate of 60% on day +56-70, and disease-free survival at 1 year of 30%. This is a single arm phase II study of upfront allogeneic stem cell transplantation, for patients with acute myeloid leukemia aged 65-75: the primary endpoint is a complete remission rate on day +56-70. The secondary endpoint is a 1-year overall disease-free survival of 30%.

NCT ID: NCT02985372 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia, Adult

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Start date: December 2016
Phase: Phase 3
Study type: Interventional

This prospective multicenter clinical study was designed to assess the efficacy and safety of decitabine in combination with low-dose cytarabine induction treatment for elderly patients with newly diagnosed acute myeloid leukemia (AML).